Drugs / Metformide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02917629 | May 2018 → Aug 2019 | carcinoma in situ of oropharynx, oral cavity carcinoma in situ, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metformide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02917629 ↗ |
| Route | Oral | “Given PO” NCT02917629 ↗ |